ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ACOR Stock Price » ACOR Stock News

Acorda Therapeutics Share News

 Acorda Therapeutics (mm) Stock Price
ACOR Stock Price
 Acorda Therapeutics (mm) Stock Chart
ACOR Stock Chart
 Acorda Therapeutics (mm) Stock News
ACOR Stock News
 Acorda Therapeutics (mm) Company Information
ACOR Company Information
 Acorda Therapeutics (mm) Stock Trades
ACOR Stock Trades

Biogen Gets Letter Of Deficiency From Health Canada On Fampridine

By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) has received a letter of deficiency from Health Canada for its application to sell the multiple sclerosis treatment fampridine in the country. The Weston, Mass., biotech company also recently received questions from the European Medicines Agency on an application to sell the same drug in the region. Biogen expects a decision later this month. The disclosures were made at the JPMorgan healthcare conference in San Francisco Tuesday by Chief Executive George Scangos. Scangos declined to comment on the letter or provide any further detail about the questions from the regulators. Fampridine helps improve walking in multiple sclerosis patients and is sold in the U.S. by Acorda Therapeutics Inc. (ACOR) under the name Ampyra. Separately, the company said that about 56,000 patients are using its MS drug Tysabri as of the end of December, an increase of 1,700 patients from fourth quarter and down from the 2,100 patients added in the third quarter. -By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com

Stock News for Acorda Therapeutics (ACOR)
DateTimeHeadline
05/20/201609:43:00U.S. Hot Stocks: Hot Stocks to Watch
05/20/201607:50:00Acorda to Discontinue Epilepsy Drug Development
05/20/201607:18:21Current Report Filing (8-k)
05/20/201606:00:00Acorda to Discontinue Development of PLUMIAZ for Treatment of...
05/18/201609:00:00Biotie Therapies Corp. to Delist Its American Depositary Shares...
05/16/201615:13:15Statement of Changes in Beneficial Ownership (4)
05/13/201609:25:28Statement of Changes in Beneficial Ownership (4)
05/13/201609:22:36Statement of Changes in Beneficial Ownership (4)
05/13/201609:19:15Statement of Changes in Beneficial Ownership (4)
05/06/201617:45:12Quarterly Report (10-q)
05/04/201607:00:00Acorda Therapeutics Named One of the Best Places to Work for...
05/02/201609:02:00Final Results of the Subsequent Offer Period of Acorda Therapeutics...
04/29/201618:16:37Proxy Statement (definitive) (def 14a)
04/29/201607:00:00Acorda Therapeutics to Present at Two Investor Conferences in...
04/28/201607:33:35Current Report Filing (8-k)
04/28/201606:00:00Acorda Provides Financial and Pipeline Update for First Quarter...
04/21/201607:59:26Statement of Changes in Beneficial Ownership (4)
04/20/201607:00:00Acorda Announces Results from Phase 2b Clinical Trial of CVT-301...
04/18/201616:38:08Current Report Filing (8-k)
04/18/201616:37:42Securities Registration: Employee Benefit Plan (s-8)

Acorda Therapeutics and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad